Q: Would appreciate your comment on this company.
You can view 3 more answers this month. Sign up for a free trial for unlimited access.
Investment Q&A
Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.
Q: It looks like Kraken Sonar started trading on the Venture Exchange on Tuesday via a reverse takeover. I was greatly impressed by the images from their sonar compared to sonar in use today (reminds me of images from Avigilon cameras compared to those in use now). Can you tell me anything else about this company.
Bryon in Elmira
Bryon in Elmira
Q: What is your take on the results released yesterday? I own it. Thank you.
Q: Hi Peter,
Would like your opinion on the new Brookfield proposal with Armtec. Assuming no buyer is found, it looks like Brookfield gets the assets for the debt and the current shareholders get to keep their shares in a company with no assets or liabilities. Very unusual!
Joe
Would like your opinion on the new Brookfield proposal with Armtec. Assuming no buyer is found, it looks like Brookfield gets the assets for the debt and the current shareholders get to keep their shares in a company with no assets or liabilities. Very unusual!
Joe
Q: Please comment if you can on today's year end report and their conference call. Company seems finally to be making good progress and have attracted 2 new funds as share buyers, according to Morningstar.
Q: Hello Peter & Team
CDV up 3+% today and up 10% over the past 10 days with a substantial increase in volume yesterday & today.
Street appears to be somewhat bullish with 60% calling it a buy and 40% saying hold.
Is there a reason you can see for the recent strength? I can't find any insider trading info... can you?
They report March 9th - what should we expect?
Thanks for all you do
Gord
CDV up 3+% today and up 10% over the past 10 days with a substantial increase in volume yesterday & today.
Street appears to be somewhat bullish with 60% calling it a buy and 40% saying hold.
Is there a reason you can see for the recent strength? I can't find any insider trading info... can you?
They report March 9th - what should we expect?
Thanks for all you do
Gord
Q: I would appreciate your outlook on the recent acquisition by Chesswood. Does this news justify adding to a partial position. The market seems to approve.
Q: What are the possible reasons for the wild price swing of the last few days. Manipulation???
Q: Hi I was wondering if I could get your opinion on this stock!
Q: I'm looking at investing in growth stocks in the pharmaceutical/health sector and am looking at two specific stocks, CRH and ACRX.US I appreciate that both are small cap and there is inherent risk in both. Could you please review each of these, provide your thoughts, and which of the two if either you would recommend.
Thank you
Jim
Thank you
Jim
Q: Is XYL far enough along for investment? It's product, Xyla, is a sugar made from hardwood by-products. This form of xylitol is recommended for the sugar-sensitive. It is anti-bacterial: candy and gum made with hardwood xylitol don't cause cavities. Last night, xylitol (in general) got a plug on The Exchange. Cookies made with xylitol will be on Whole Foods shelves. This tells me public awareness is growing. Is XYL strong enough to grow? From Patti.
Q: Could you please give your opinion on their latest 1/4ly report and would you buy/hold/or sell.
Thanks
Thanks
Q: I'd like to know what your current view is on MCR. In response to a question I posed on Dec 9/14 the answer was "Macro had a very tough year; even before the recent energy sector meltdown, it experienced cost overruns on a fixed cost project, and this destroyed its profit margins. Now, sector retrenchment means there will likely be fewer opportunities for growth over the next two years. But.....it is still profitable, and very cheap. It has some debt, which may be more of a concern if there is not a recovery. After its big drop, we would consider it a hold, but would not buy any more. Note however that its small size now adds some more risks, especially in the short term while the sector tries to stabilize. We think it survives this cycle, but you will likely need to commit to it for another two years."
Yet, in a response to another persons question on Jan 16/15 you respond: "...Both stocks are very, very cheap, reflecting the debt and the sector. As far as survivability goes, much depends on how long the sector situation lasts. MCR, likely, has a better ability to reduce costs, as CET owns its equipment and when business slows it earns nothing on unused equipment. MCR insiders have much more skin in the game than CET insiders.
With the risk of the dividend cut hurting CET, we would reluctantly side with MCR today. But neither looks particularly interesting to us anymore. "
I realize that not the same person answers questions, and there was a period of time between those questions, and now...
What is your current view? Is it worth holding, or time to sell while I can still get something out of it.
Thanks for everything! Love your service!
Yet, in a response to another persons question on Jan 16/15 you respond: "...Both stocks are very, very cheap, reflecting the debt and the sector. As far as survivability goes, much depends on how long the sector situation lasts. MCR, likely, has a better ability to reduce costs, as CET owns its equipment and when business slows it earns nothing on unused equipment. MCR insiders have much more skin in the game than CET insiders.
With the risk of the dividend cut hurting CET, we would reluctantly side with MCR today. But neither looks particularly interesting to us anymore. "
I realize that not the same person answers questions, and there was a period of time between those questions, and now...
What is your current view? Is it worth holding, or time to sell while I can still get something out of it.
Thanks for everything! Love your service!
Q: Hi Peter and Team, regarding AHF, would you consider the stock a soft hold, a strong hold or simply a sell into this current strength? Almost at break even at .90 cents. Thanks!
Q: Hi Peter,
Sylogist declared quite good results and they did an equity offering for 11 cad. They did a few acquistions too if I am not mistaken. Conventional wisdom states that a company grows by acquistions case in point csu,valient, Amaya so why is sylogist not following. They also increased their dividend what else do they have to do to increase their share value your
comments will be appreciated.
Thanks
Paul
Sylogist declared quite good results and they did an equity offering for 11 cad. They did a few acquistions too if I am not mistaken. Conventional wisdom states that a company grows by acquistions case in point csu,valient, Amaya so why is sylogist not following. They also increased their dividend what else do they have to do to increase their share value your
comments will be appreciated.
Thanks
Paul
Q: Please provide comments on their earnings and how the stock might react? Any change in the future picture?
Q: convalo has 76 million warrants that have to be exercised at 20 cents i think in the next 2 weeks. my question is convalo hit an intraday high of .385 cents, but i would think it would sell off considerably as shareholders sell the stock to exercise the warrants. am i right or wrong. dave
Q: Hi Peter and Co.
I looked at VNP numbers from last night's earnings release and I'm trying to find a positive somewhere in them but I'm struggling mightily. They look pretty awful. I suppose the only positive is that the stock isn't down more today.
Your thoughts?
Thanks,
Michael
I looked at VNP numbers from last night's earnings release and I'm trying to find a positive somewhere in them but I'm struggling mightily. They look pretty awful. I suppose the only positive is that the stock isn't down more today.
Your thoughts?
Thanks,
Michael
Q: You previously told a subscriber you expected these guys to raise money soon and they have as of today but does this generally help or hinder stock prices uniformly as it is down 13 cents today. Do you think this makes it any less speculative.
Q: I would appreciate your assessment of Biosyent's earnings release issued this morning. Thank you, Peter